Targeting vector of M2 type macrophage and application

The M2pep-rHF-KLA recombinant protein nanoparticles induces M2 macrophages to polarization to M1 type, solving the problem of lack of targeting and biological toxicity in the application of inorganic nanoparticles in vivo, and achieving safe and effective macrophage poles and promote anti-tumor immunotherapy.

CN118976115APending Publication Date: 2024-11-19EIGHTH AFFILIATED HOSPITAL SUN YAT SEN UNIV (SHENZHEN FUTIAN)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410459149.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-17
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing inorganic nanoparticles lack targeting and biotoxicity in vivo, making it difficult to effectively induce macrophages to polarize in specific directions, especially in anti-tumor immunotherapy, which is more challenging to induce M2 type macrophages to M1 type. big.

Method used

M2pep-rHF-KLA recombinant protein nanoparticles were used to fuse M2 macrophage targeting peptides and KLA short peptides at the amino terminus of human heavy chain ferritin rHF to form M2pep-rHF-KLA recombinant protein nanoparticles for use in Induce polarization of M2 macrophages to M1 type.

Benefits of technology

It has achieved safe and effective targeting induction of M2 macrophages, and has constructed an M2 TAM targeting vector suitable for system use, which can induce M2 macrophages to polarize to M1 without combining other drugs, and Cell viability has little effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976115A_ABST
    Figure CN118976115A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedicine, and particularly discloses a targeting vector of M2 type macrophages, the targeting vector is M2pep-rHF-KLA recombinant protein nanoparticles, the amino acid sequence of the recombinant protein is as shown in SEQ ID NO. 2, and the gene sequence for coding the M2pep-rHF-KLA recombinant protein nanoparticles is as shown in SEQ ID NO. 1. The compound can induce polarization of M2 type macrophages to M1 type macrophages, and has no obvious influence on the activity of RAW264.7 and THP-1 macrophage lines; a safe and effective M2 type TAM targeting vector is constructed, and the recombinant protein can be massively expressed in escherichia coli and is suitable for large-scale production; meanwhile, the M2pep-rHF-KLA nanoparticles can be independently used, and the M2 type macrophages can be induced to be polarized to the M1 type macrophages without being combined with other medicines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and in particular relates to a targeting vector for M2 macrophages and an application thereof. Background Art

[0002] Macrophages are a type of cell with multiple differentiation sources and are distributed throughout the body. They are one of the important components of the body's innate immune system. They have the functions of phagocytosis, antigen presentation, and secretion of a variety of cytokines. They play an important role in physiological processes such as inflammation, defense, repair, and metabolism, and maintain the body's own stability. Macrophages are highly plastic and multipotent. Under the influence of different microenvironments in the body, they show characteristics such as local tissue function specificity and abnormal differentiation induced by inflammatory factors. According to the different activation states and functions, macrophages can be mainly divided into classically activated macrophages (M1 type) and alternatively activated macrophages (M2 type). M1 macrophages show strong pro-inflammatory and antigen-presenting abilities, secrete a large number of pro-inflammatory factors, including IL-1, IL-6, tumor necrosis factor-α (TNF-α), nitric oxide synthase (iNOS), etc., and play a host immune clearance function against pathogens and tumor cells. M2 macrophages can release a large number of cytokines such as vascular endothelial growth factor (VEGF), arginase-1 (Arg-1), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β) and IL-10, which have the effects of anti-inflammatory, promoting wound healing and fibrosis, repairing tissues, and promoting tumor growth and infiltration.

[0003] Macrophage polarization is involved in the process of many diseases (such as tumors, rheumatoid arthritis, inflammatory diseases of the lungs and kidneys, burns, obesity, etc.). Inducing macrophage polarization in a specific direction is of great significance for the treatment and prevention of various inflammatory diseases. For example, tumor-associated macrophages (TAMs) are mainly M2-type, which are an important part of the tumor immune microenvironment and affect the angiogenesis, tumor cell metastasis and anti-tumor immunosuppression of malignant tumors. Therefore, inducing the conversion of M2-type TAMs to M1-type and clearing or inhibiting M2-type TAMs are important strategies for anti-tumor immunotherapy.

[0004] M1 and M2 types can be formed under the stimulation of specific drugs or biological signals. Under in vitro culture conditions, dormant macrophages (M0) can be polarized into M1 macrophages by IFN-γ and LPS; polarized into M2a under the induction of IL-4 or IL-13; polarized into M2b under the induction of immune complexes; and polarized into M2c under the induction of anti-inflammatory cytokine IL-10. In addition, some inorganic nanoparticles are easily taken up by macrophages due to their unique physical and chemical properties, which can induce macrophages to polarize in a specific direction. For example, inorganic nanoparticles such as gold, silver, iron oxide, ZnO, Ti, Co, and SiO2 that can induce the production of reactive oxygen species (ROS) can induce macrophages to polarize into M1 type. Chromium oxide, copper, and cerium oxide nanoparticles that can inhibit the production of ROS can induce macrophages to polarize into M2 type. However, the in vivo application of inorganic nanoparticles lacks targeting, and their in vivo biological toxicity also limits their application. Therefore, there is an urgent need to develop new safe, effective, and system-friendly macrophage-targeted transport platforms and new materials that can induce macrophage polarization in a specific direction.

[0005] Ferritin is a caged protein nanoparticle widely found in a variety of organisms. It has good biocompatibility and physical and chemical properties such as resistance to acid and alkali changes and heat resistance, and has the advantage of being easy to modify. Human heavy chain ferritin (rHF) can self-assemble into a 24-mer protein cage structure. The cage structure is a cavity with an outer diameter of 12nm and an inner diameter of 8nm. The amino terminus of the protein subunit is displayed on the outer surface of the cage structure, and the carboxyl terminus is encapsulated inside the cavity. rHF can encapsulate a variety of inorganic particles and small molecule drugs and is widely used as a drug delivery carrier. Modification of the surface of nanoparticles with groups such as mannose, galactose or M2 targeting peptide M2pep can enhance the targeting effect of nanoparticles on macrophages.

[0006] Therefore, the present invention provides a targeting vector for M2 macrophages to induce the polarization of M2 macrophages to M1 macrophages. Summary of the invention

[0007] In order to solve the above technical problems, the present invention proposes a targeting vector for M2 macrophages, which is used to induce the polarization of M2 macrophages into M1 macrophages.

[0008] In order to achieve the above object, the present invention is achieved through the following technical solutions:

[0009] The present invention provides a targeting vector for M2 macrophages, wherein the targeting vector is M2pep-rHF-KLA recombinant protein nanoparticles, the amino acid sequence of the recombinant protein is shown in SEQ ID NO.2, and the gene sequence encoding the M2pep-rHF-KLA recombinant protein nanoparticles is shown in SEQ ID NO.1.

[0010] The present invention also provides a method for preparing the above-mentioned targeting vector, which comprises the following steps:

[0011] S1: The amino terminus of human heavy chain ferritin rHF was fused with an M2 macrophage targeting peptide, and the carboxyl terminus was fused with a KLA short peptide, amplified using primers, and the amplified product was digested and inserted into the expression vector pET32a to obtain the M2pep-rHF-KLA protein expression plasmid;

[0012] S2: The M2pep-rHF-KLA protein expression plasmid was transformed into the Escherichia coli expression system for expression, and after induction and purification, the M2 macrophage targeting vector M2pep-rHF-KLA recombinant protein nanoparticles were obtained.

[0013] Preferably, in the S1, the M2pep targeting peptide (YEQDPWGVKWWY) is connected to the amino terminus of the human heavy chain ferritin rHF using a GSG linker, and the KLA short peptide (KLAKLAK)2 is fused to the carboxyl terminus using a GSG linker.

[0014] The present invention also provides use of the above-mentioned targeting carrier M2pep-rHF-KLA recombinant protein nanoparticles in inducing polarization of human M2 macrophages into M1 macrophages.

[0015] The beneficial effects of the present invention are:

[0016] The M2 macrophage targeting vector proposed in the present invention, namely the M2pep-rHF-KLA recombinant protein nanoparticles, can induce M2 macrophages to polarize toward M1 macrophages, and has no significant effect on the viability of RAW264.7 and THP-1 macrophage cell lines; a safe and effective M2 TAM targeting vector is constructed, and the recombinant protein can be expressed in large quantities in Escherichia coli, which is suitable for large-scale production; at the same time, the M2pep-rHF-KLA nanoparticles can be used alone, without the need to be combined with other drugs, to induce M2 macrophages to polarize toward M1 macrophages. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for describing the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative work.

[0018] Figure 1 Schematic diagram of the construction of M2pep-rHF-KLA recombinant protein;

[0019] Figure 2It is the SDS-PAGE electrophoresis diagram of the purified M2pep-rHF-KLA and rHF recombinant proteins;

[0020] Figure 3 Transmission electron microscopy characterization of M2pep-rHF-KLA and rHF recombinant protein nanoparticles, the scale bar is 50 nm;

[0021] Figure 4 Dynamic light scattering (DLS) characterization diagram of M2pep-rHF-KLA and rHF nanoparticles;

[0022] Figure 5 Figure 1 is a graph showing the cytotoxicity of M2pep-rHF-KLA nanoparticles to RAW264.7 and THP-1 cells. Figure A shows the cytotoxicity of M2pep-rHF-KLA nanoparticles at different concentrations to RAW264.7 cells. Figure B shows the cytotoxicity of M2pep-rHF-KLA nanoparticles at different concentrations to THP-1 cells.

[0023] Figure 6 RT-qPCR statistical graph of the mRNA expression of M1 and M2 cell markers in M1 macrophages or M2 macrophages differentiated from human macrophage cell line THP-1 after induction with M2pep-rHF-KLA nanoparticles;

[0024] Figure 7 Figure 3 shows the flow cytometric analysis of the ratio of M1 and M2 macrophages after induction of M2pep-rHF-KLA nanoparticles in M1 or M2 macrophages differentiated from human peripheral blood monocytes (Figure A) and the statistical graph of the M1 / M2 cell ratio (Figure B). DETAILED DESCRIPTION

[0025] The embodiment of the present invention describes in detail a method for preparing a targeting vector for M2 macrophages, namely, M2pep-rHF-KLA recombinant protein nanoparticles, and its demonstration process in inducing polarization of M2 macrophages into M1 macrophages. The technical solutions described in the embodiments of the present invention are conventional solutions in the art unless otherwise specified.

[0026] Example 1 Preparation and Characterization of M2pep-rHF-KLA Recombinant Protein Nanoparticles

[0027] (1) Construction of M2pep-rHF-KLA recombinant protein expression plasmid pET32a / M2pep-rHF-KLA

[0028] like Figure 1As shown in FIG. 1 , the M2pep targeting peptide (YEQDPWGVKWWY) was connected to the amino terminus of human heavy chain ferritin (rHF) with a GSG linker, and the KLA short peptide (KLAKLAK) was fused to the carboxyl terminus with a GSG linker 2 to obtain the M2pep-rHF-KLA recombinant protein. The expression vector was constructed as follows: using the plasmid pET28a-rHF encoding rHF (completely synthesized by Guangzhou Qingke Biotechnology Co., Ltd.) as a template, the forward primer (5'GGAATTCCAT ATGTATGAACAGGATCCGTGGGGCGTGTTTTGGTGGTATGGCTCA GGTACGACCGCGTCCACCTCGC 3') and the reverse primer (5'CCCTCGAG TTACTTCGCCAGTTTCGCCAGTTTCTTCGCCAGTTTCGCCAGTTT ACCTGAGCCTCCCAGGGTGTGCTTGTC 3') were used to amplify the nucleotide sequence of M2pep-rHF-KLA by PCR (shown in SEQ ID NO. 1). The amplified product was double digested with Nde1 and Xho1 and then inserted into the expression vector pET32a to obtain the expression plasmid pET 32a / M2pep-rHF-KLA. Finally, the correctness of the target gene sequence was verified by sequencing.

[0029] (2) Expression and purification of recombinant proteins

[0030] The constructed plasmid pET32a / M2pep-rHF-KLA was transformed into E. coli Rosetta (DE3) and cultured in LB medium at 37°C and 180 rpm until OD 600 At 0.4-0.6, IPTG was added to a final concentration of 1mM, and the induction was continued at 16°C and 180rpm for 18h. Then, the cells were collected by centrifugation at 4°C and 5000g for 10min, and the cells were resuspended in pre-cooled assembly buffer (20mM Tris, 50mM NaCl, HCl adjusted to pH 8.0). After ultrasonic disruption on ice for 40min, the cells were centrifuged at 10,000g for 30min, and the supernatant was collected and purified with a His-trap affinity column. The eluted protein solution was placed in the assembly buffer and dialyzed at 4°C for 24h, and the solution was changed three times. The purified protein was concentrated with an ultrafiltration tube (Millipore, MW cut off 100kDa), and the protein concentration was detected with a BCA protein detection kit (Biyuntian). After induction and purification, about 20mg of M2pep-rHF-KLA protein can be purified from 1L of bacterial solution.

[0031] (3) Detection of purified M2pep-rHF-KLA protein by SDS-polyacrylamide gel electrophoresis (SDS-PAGE)

[0032] The predicted size of M2pep-rHF-KLA protein is 38.5 kDa. Using purified rHF (21 kDa) as a control, the band of M2pep-rHF-KLA monomer can be seen between 37 and 50 kDa ( Figure 2 ).

[0033] (4) Transmission electron microscopy characterization of assembled M2pep-rHF-KLA protein nanoparticles

[0034] The copper mesh was adsorbed on a drop of 0.5 mg / mL M2pep-rHF-KLA nanoparticles for 1 min, the solution at the edge of the copper mesh was gently removed with filter paper, and then stained with 2% phosphotungstic acid (pH 7.4) for 5 min. Finally, the copper mesh was placed in the air to dry naturally and detected with a 200 kV transmission electron microscope. The transmission electron microscope images show that M2pep-rHF-KLA, like pure rHF, can be assembled into a monodisperse spherical structure ( Figure 3 ).

[0035] (5) Dynamic light scattering (DLS) characterization of the hydrated particle size of assembled M2pep-rHF-KLA nanoparticles

[0036] like Figure 4 As shown, the particle sizes of rHF and M2pep-rHF-KLA nanoparticles are 12.92±0.31nm and 19.41±1.53nm, respectively. Further testing of the zeta potential of each nanoparticle revealed that the zeta potential of rHF and M2pep-rHF-KLA nanoparticles were -10.77±0.83mV and -16.37±1.00mV, respectively.

[0037] Example 2 Cytotoxicity Detection of M2pep-rHF-KLA Nanoparticles

[0038] The Cell Counting Kit-8 (CCK-8) detection kit was used to detect the toxicity of M2pep-rHF-KLA nanoparticles on mouse mononuclear macrophage leukemia cells RAW264.7 and human mononuclear leukemia cells THP-1 cell lines. The specific steps are as follows: 5000 living cells were added to a 96-well plate and incubated in an incubator for 12 hours to allow the cells to adhere. The cells were treated with M2pep-rHF-KLA nanoparticles at concentrations of 0.1, 0.3, 0.5, 1, and 2 μM, respectively, and the control group was treated with an equal volume of phosphate buffered saline (PBS). After incubation for 48 hours, 10 μL of CCK-8 solution was added to each well. After 4 hours, the OD was detected using an enzyme reader. 450 Finally, the relative cell viability was calculated according to the following formula:

[0039] Relative cell viability = N sample / N control (N sample is the number of live cells in the sample, N control is the number of live cells in the PBS-treated group).

[0040] like Figure 5 The cytotoxicity assay results shown in the figure showed that different concentrations of M2pep-rHF-KLA nanoparticles had no significant effect on the viability of RAW264.7 and THP-1 cell lines.

[0041] Example 3 Cell-based detection of the ability of M2pep-rHF-KLA nanoparticles to polarize M2 macrophages to M1 macrophages

[0042] (1) Detection of the expression of M1 and M2 macrophage markers in human macrophage cell line THP-1 induced by M2pep-rHF-KLA nanoparticles

[0043] Human macrophage cell line THP-1 cells were stimulated with PMA, LPS, and IFN-γ to differentiate into M1 macrophages or with PMA, IL-4, and IL-13 cytokines to differentiate into M2 macrophages. M2pep-rHF-KLA nanoparticles with a final concentration of 0.5 μM were added to the induced M1 macrophages or M2 macrophages, and the control group was treated with an equal volume of PBS. After 24 hours of induction, the cells were collected. Total RNA was then extracted and reverse transcribed into cDNA. Fluorescence quantitative PCR was used to detect the expression of human M1 macrophage markers HLA-DR, IL-6, TNF-α genes and M2 macrophage markers CD163 and CD206 genes. The results were expressed in 2 – ΔΔCT The primer sequences of the relevant genes are shown in Table 1.

[0044] Table 1 Primer sequences of human M1 and M2 TAM-related genes

[0045]

[0046] like Figure 6 The results showed that after induction by M2pep-rHF-KLA nanoparticles, the expression of M1 macrophage markers HLA-DR, IL-6, and TNF-α in THP-1 cells increased significantly, and the increase was more significant in M2 macrophages; while the expression of M2 macrophage markers CD163 and CD206 genes was significantly decreased in M2 macrophages, indicating that M2pep-rHF-KLA nanoparticles can induce the polarization of the human macrophage cell line THP-1 from M2 to M1.

[0047] (2) Effects of M2pep-rHF-KLA nanoparticles on polarization of M1 and M2 macrophages differentiated from human peripheral blood mononuclear cells (PBMCs)

[0048] Peripheral blood mononuclear cells (PBMC) were isolated and M1 and M2 macrophages were induced. The specific method was as follows: 15 mL of whole blood was collected from healthy volunteers, and PBMCs were separated by density gradient centrifugation (460g, 30 min) using Ficoll-Plaque reagent (GE healthcare, Sweden). The isolated PBMCs were then washed three times with PBS and cultured in RPMI-1640 medium containing 10% (volume percentage) fetal bovine serum (FBS). Finally, PBMCs were treated with lipopolysaccharide (LPS), granulocyte-macrophage colony stimulating factor (GM-CSF), and gamma-interferon (IFN-γ) to induce differentiation of PBMCs into M1 macrophages; or treated with interleukin 4 (IL-4), interleukin 13 (IL-13), and macrophage colony stimulating factor (M-CSF) to induce differentiation of PBMCs into M2 macrophages.

[0049] M2pep-rHF-KLA nanoparticles were added to M1 or M2 macrophages differentiated from PBMCs for stimulation, and the control group was treated with an equal volume of PBS. After 24 hours, the cells were collected. Then, the components of M1 and M2 macrophages were detected by flow cytometry. + CD80 + CD86 + The cells are mainly M1 macrophages, and CD14 + CD163 + CD206 + The cells are mainly M2 macrophages, so the ratio of M1 / M2 cells can be measured by CD14 + CD80 + CD86 + / CD14 + CD163 + CD206 + The ratio of cells was calculated.

[0050] like Figure 7 The results showed that compared with the control group, the ratio of M1 / M2 cells in M2 macrophages increased significantly after treatment with M2pep-rHF-KLA (0.118 vs. 1.671); while the ratio of M1 / M2 cells did not change significantly after treatment with M2pep-rHF-KLA. This indicates that M2pep-rHF-KLA can induce human M2 macrophages to polarize to M1, while having no significant effect on M1 macrophages.

[0051] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all details in detail, nor do they limit the invention to only the specific embodiments described. Obviously, many modifications and changes can be made according to the content of this specification.

Claims

1. A targeting vector for M2 macrophages, characterized in that: The targeting vector is M2pep-rHF-KLA recombinant protein nanoparticles, the amino acid sequence of the recombinant protein is shown in SEQ ID NO.2, and the gene sequence encoding the M2pep-rHF-KLA recombinant protein nanoparticles is shown in SEQ ID NO.

1.

2. A method for preparing the M2 macrophage targeting vector according to claim 1, characterized in that: The following steps are involved: S1: The amino terminus of human heavy chain ferritin rHF was fused with an M2 macrophage targeting peptide, and the carboxyl terminus was fused with a KLA short peptide, amplified using primers, and the amplified product was digested and inserted into the expression vector pET32a to obtain the M2pep-rHF-KLA protein expression plasmid; S2: The M2pep-rHF-KLA protein expression plasmid was transformed into the Escherichia coli expression system for expression, and after induction and purification, the M2 macrophage targeting vector M2pep-rHF-KLA recombinant protein nanoparticles were obtained.

3. The method for preparing the targeting vector for M2 macrophages according to claim 2, characterized in that: In the S1, the M2pep targeting peptide is connected to the amino terminus of the human heavy chain ferritin rHF using a GSG linker, and the KLA short peptide is fused to the carboxyl terminus using a GSG linker.

4. Use of the M2 macrophage targeting vector according to any one of claims 1 to 3 in inducing polarization of human M2 macrophages into M1 macrophages.